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Abstract
LEDGF/p75 is an important cellular co-factor for lentiviral integration. LEDGF/p75-deficient
cells are markedly resistant to HIV-1 infection and re-expression of the wild type protein rescues
infectivity. Although the molecular mechanism of LEDGF/p75 in HIV-1 integration is not yet
known, this co-factor activity requires the interaction of LEDGF/p75 with both the host
chromatin and viral integrase. In order to evaluate the involvement of other LEDGF/p75 regions
in HIV-1 infection we constructed a panel of deletion mutants targeting clusters of charged
residues that are evolutionarily conserved and predicted to be post-translationally modified.
These mutants were evaluated for their ability to rescue HIV-1 infection in a LEDGF/p75deficient human T cell line (TL3 cells) and to interact with chromatin and integrase. Our results
indicate that serine residues 271, 273, and 275 are involved in the HIV-1 cofactor role of
LEDGF/p75. HIV-1 infection is impaired in LEDGF/p75-deficient CD4+ T cells expressing the
LEDGF/p75 mutant S271A/S273A/S275A to levels observed with LEDGF/p75 mutants where
chromatin binding is deficient. However, this mutation did not affect chromatin or integrase
binding. More importantly, this mutant tethers EGFP-tagged integrase to the host chromatin in
cells. According to five different global phosphoproteomic studies done by other laboratories,
these residues are targeted for phosphorylation in both human and mouse cells. In correlation
with this, in silico analysis predicted that these serine residues are a substrate for Protein Kinase
Casein Kinase II. This data strongly suggests that the role of LEDGF/p75 in HIV-1 integration
may also involve other protein functions in addition to integrase and chromatin binding.
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Chapter 1: General Introduction
1.1

HIV-1 Life Cycle

HIV-1 is a retrovirus that enters target cells after fusion of viral and cellular membranes.
Fusion is mediated by a specific interaction of glycoproteins on the surface of the virus with
receptors on the cell’s surface. Once the viral RNA genome is successfully released into the
cytosol of the host cell, it is then immediately reverse transcribed into double-stranded cDNA
containing a copy of the viral long terminal repeat (LTR) at each end. This viral DNA associates
with viral and cellular proteins to form a nucleoprotein complex known as the preintegration
complex (PIC), which is translocated into the nucleus. Integration of the viral DNA into the host
chromatin is then catalyzed by the viral enzyme integrase (IN), which performs two enzymatic
activities essential for viral integration; 3’ processing of the viral DNA and DNA strand transfer
of the viral genome into the host chromatin. 3’ processing occurs soon after reverse transcription
when a dinucleotide from each HIV-1 LTR is cleaved off, leaving two sticky ends on either end
of the viral DNA [1, 2]. IN’s second enzymatic activity, DNA strand transfer, takes place after
the PIC enters the nucleus and locates a suitable integration site resulting in viral integration [3].
After strand transfer, single stranded gaps flank the ends of the viral genome. Efficient viral
integration requires DNA repair of the gaps by host repair machinery. Only after integration can
the viral genome be efficiently transcribed and new progeny produced, making integration a
crucial step in HIV-1 infection [4] (Fig.1).
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Figure 1. HIV-1 life cycle. Human immunodeficiency virus (HIV) is a retrovirus that can lead to
acquired immunodeficiency syndrome (AIDS), a condition in humans in which the immune
system begins to fail, leading to life-threatening opportunistic infections (google images, 2007).
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1.2.

Molecular Aspects of HIV-1 Viral Entry
The entry of HIV-1 into target cells requires the binding of the outer envelope

glycoprotein (gp120) to the CD4 receptor [5] and a coreceptor, CCR5 [6] or CXCR4 [7]. gp120
is composed of five conserved regions (C1-C5) and five hypervariable regions (V1-V5) [8].
This protein is heavily glycosylated with 50% of its molecular mass made up of carbohydrates
and contains between 20-25 recognition sites for N-linked glycosylation [9]. N-glycans within
gp120 play roles in both viral entry and in shielding the virus against neutralizing antibodies
[10].
gp120 contains five loops (V1-V5) with V3 being the most immunodominant and most
targeted by neutralizing antibodies [10]. This loop interacts with both co-receptors, CCR5 and
CXCR4 [11]. N-Glycans within V1 and V2 (g2-g7) are thought to act as a barrier by preventing
binding of V3-specific neutralizing antibodies to the V3 loop [12]. It has been demonstrated that
N-glycans within the V1/V2 variable regions of gp120 are indispensable for both maintaining
viral functionality and acting as masking epitopes against neutralization [12]. In a study done by
Wolk et al it was shown that N-glycans g4, g5, g6 and g7 were important for viral infectivity
since mutants lacking these N-glycans were highly deficient in viral entry. It was also shown that
mutants lacking g2, g3, g5 and g6 were highly sensitive to neutralizing antibodies meaning that
these N-glycans play a role in shielding HIV-1 from neutralizing antibodies [12].
Once gp120 binds to its receptor (CD4) and co-receptor (CCR5 or CXCR4) a
conformational change is triggered that causes the insertion of the hydrophobic N-terminus of
gp41 into the target cell membrane [13]. This HIV-1 transmembrane protein (gp41) typically
contains three to four highly conserved sites for N-glycan attachment which are located in a short
stretch of amino acids (20 to 30 residues) [14]. Experimental data has demonstrated that these
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sites are largely dispensable for HIV-1 replication. This was shown in an elegant study done by
Johnson et al in which they systematically mutated the N-glycan attachment sites of gp41 not
only individually but also in all possible combinations and then measured the effect of each of
these mutants on viral replication. What they reported was that only the quadruple mutant
(g1234) in which all four asparagines residues which serve as N-glycan attachment sites were
mutated to glutamine residues did not replicate in any cell line and were also not fusogenic [14].
The reason behind this mutation was the fact that glutamine is structurally similar to asparagines,
differing by only a single methylene group.

4

1.3.

Molecular Aspects of HIV-1 Integration
Integrase performs two major catalytic activities: 3’-processing, an endonucleolytic

cleavage at each 3’-OH end of the viral cDNA and a strand transfer reaction, which leads to the
insertion of the processed viral DNA into the target DNA. Once integrated, the provirus persists
in the host cell and serves as a template for the transcription of viral genes and replication of the
viral genome leads to the production of new viral progeny.
Post-integration repair (PIR) is an essential step in the retroviral lifecycle [15]. PIR
occurs after 3’-processing and DNA strand transfer. An intermediate is produced during the
initial integrase-mediated linkage that occurs between the viral and host DNA in which the
proviral DNA is flanked by short, single-stranded gaps in the host-cell DNA. Integration is then
completed by PIR which is composed of four distinct steps: (1) trimming of the 2-bp flaps from
the 5’-ends of the proviral DNA, (2) filling in of the single-stranded gaps, (3) ligation of the
trimmed 5’-ends to the filled in host DNA strands, and (4) reconstitution of the appropriate
chromatin structure at the integration site [15, 16].
It has been proposed that Nijmegen breakage syndrome-1 protein (NBS1), which is one
of the earliest known sensors of double-stranded DNA breakage (DSB) is involved in HIV-1
PIR. Smith et al. demonstrated that NBS1 associates with viral DNA and mediates efficient
integration. They also proposed that retroviral PIR employs the non-homologous end joining
(NHEJ) pathway (Fig. 2).
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Figure 2. NHEJ Pathway. DNA double stranded breakage in which the DNA ends are non
homologous are mainly repaired through the NHEJ pathway. This pathway employs a number of
proteins including Ku, DNA-PKcs, and Ligase IV in order to repair DNA lesions [15].
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The NHEJ pathway is a repair mechanism used by cells to repair DSB [17]. This pathway
employs several proteins that function in concert with each other to repair DNA damage. Once a
DSB occurs, Ku, a heterodimer that is an abundant DNA-binding protein with ATPase activity,
binds strongly to the DNA ends. Ku then recruits to the DNA ends DNA-PKcs which is trimeric
protein consisting of DNA-PKcs, Ku70, and Ku86. Artemis, which is a substrate of DNA-PK, is
then recruited by DNA-PKcs, which then phosphorylates Artemis along with itself. XRCC4,
which is another protein recruited by Ku whose recruitment is independent of DNA-PKcs and
Artemis, then recruits DNA Ligase IV thus allowing the ends of the DSB to be ligated together
[18, 19].
It has been proposed by a number of laboratories that PIR hijacks the host cell’s DSB
pathways thus allowing retroviruses such as HIV-1 to fully integrate their viral DNA within that
of the host cell (Fig. 3).
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Figure 3. Post Integration Repair. According to the model proposed by Smith et al. this process
incurs a number of steps. (1) First, integrase catalyzes the formation of the integration
intermediate within the host cells’s DNA, (2) NBS1 and ataxia talangiectasia-mutated kinase
(ATR) are then each independently recruited to the site of integration, (3) NBS1 then recruits
other proteins such as MREI I, RAD50, and ATM to the integration site, (4) the 5’-end DNA
flaps of the proviral DNA are then trimmed and ATM phosphorylates H2AX (although it was
found that this step is dispensable for PIR), (5) it is then thought that the Artemis and NHEJ
proteins are recruited to the site of integration and that these proteins along with other cellular
factors mediate the final steps of PIR. These steps could include further end processing, gap
filling, ligation and chromatin remodeling [15].
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Initial studies on PIR have shown that it seems to use a somewhat different type of
cellular machinery than DSB repair. For instance DSB repair requires the phosphorylation of
histone H2AX which is mediated by the ATM and ATR kinases but in the case of PIR this step
appears to be dispensable [20]. Another difference between DSB and PIR is that DSB requires
both NBS1 and ATM to recruit ATR but in regard to PIR it is recruited independently of these
two proteins, this difference in ATR recruitment could be explained by the thought that the
single stranded DNA gaps, which flank the integration site, are sufficient to recruit the ATR
protein [15].

9

1.4.

HIV-1 Vaccine Strategies
So far, all attempts to develop an effective vaccine against HIV-1 have failed. This is

mainly due to high mutational rate presented by the virus allowing it to escape immunological
surveillance [21-23]. Glycans present on the viral envelope have a crucial role in enabling the
virus to efficiently fuse to target cells in order to insert its genome within the host [24]. These
glycans also function to disguise the virus from the immune system by acting as “self” antigens
on the viral surface [25]. Therefore agents that interact with these glycans could not only
interfere with viral entry but also allow the virus’s envelope glycan shield to be breached thus
allowing previously shielded immunodominant epitopes of the viral envelope to be recognized
by the immune system [26]. These carbohydrate-binding agents (CBAs) may serve as an
important tool in vaccine development against HIV-1 [23].
It has been postulated that CBAs could be the first chemotherapeutics with a dual
mechanism of antiviral action. First, through direct antiviral activity by binding directly to
glycans on the virus’s surface thus blocking viral entry and second through indirect antiviral
activity resulting from a progressive loss of protective glycans from the viral envelope allowing
for an immune response to take place against previously hidden immunogenic epitopes in the
viral envelope [23].
CBAs can inhibit HIV-1 infection of dendritic cells (DCs) and DC-directed HIV-1
transfer [27]. This transfer takes place during the initiation of infection when DCs present at the
site of viral entry (skin dermis, placenta, and genital mucosa) capture HIV-1 virions through their
DC-SIGN receptors and present them to immature T cells in the draining lymph nodes [23]. At
the moment of presentation virus particles are present at the cell-cell junctions and this is thought

10

to act as an infectious synapse in which the passage of virions between the two cell types is
facilitated, thus causing infection of T cells [28].
There has been much evidence indicating that the glycan shield present on the viral
envelope helps the virion escape immune surveillance [23]. HIV-1 strains lacking the highly
conserved N-linked glycan at position 306 within the V3 loop of gp120 are highly sensitive to
neutralization [29]. Studies with SIVmac239, a stain of simian immunodeficiency virus that is
highly resistant to neutralization by polyclonal antisera and monoclonal antibodies have shown
that the elimination of N-glycan attachment sites within gp120 result in a dramatic increase in
sensitivity to neutralization by monoclonal antibodies [30]. These results indicate that the
deletion of as few as two N-glycans within the viral envelope can trigger a significant immune
response [23].
CBAs directly interact with glycans present on the envelope gp120 of HIV-1. This
interaction progressively forces the virus to delete N-glycans in gp120 in an attempt to escape
recognition and in doing so exposes viral epitopes previously hidden, thus triggering an immune
response to neutralize the invading pathogen. It is important to note that CBAs do not need to be
taken up by a virus-infected cell in order to exert their antiviral activity and in turn do not disturb
natural cellular glycan formation [23].
To date, no existing antiviral chemotherapeutic has demonstrated the ability to work in
concert with the patient’s immune system to further increase therapeutic pressure on mutated
forms of the HIV-1 virus. Therefore CBAs have the potential to become the first strategy to
combine drug mediated virus suppression with the induction of a specific immunological
response to the pathogen [26].
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1.5.

LEDGF/p75’s Involvement in HIV-1 Integration
HIV-1 integration is a complex phenomenon that requires the concerted action of viral

and cellular proteins. The lens epithelium-derived growth factor/p75 (LEDGF/p75) is a cofactor for lentiviral integration. LEDGF/p75 is a nuclear protein that belongs to the family of
hepatoma-derived growth factors. This HIV-1 cofactor is an alternatively spliced product from
the gene, PSIP1 [31, 32]. Increased interest has drawn among HIV-1 researchers since the
discovery that this protein interacts with HIV-1 integrase (Fig. 4) [33]. Subsequently, it was
demonstrated that LEDGF/p75 is essential for HIV-1 integration (Fig. 5) [4]. In this study, it was
found that HIV-1 target cells deficient in LEDGF/p75 were resistant to HIV-1 integration and
therefore to infection [4]. Infectivity was rescued in these cells by re-expression of LEDGF/p75
wild type but not of mutants impaired in their chromatin or integrase binding activity. It was then
postulated that LEDGF/p75 acts as a molecular tether attracting the nuclear imported PIC to the
host chromatin (Fig. 6).
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Figure 4. LEDGF/p75 interacts with HIV-1 integrase. HIV-1 IN is un-tethered from chromatin
by depletion of LEDGF/p75 and displays a pancellular distrubution within the cell [34].
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Figure 5. LEDGF/p75 is essential for HIV-1 infection. (a) LEDGF/p75 reexpression in
LEDGF/p75 deficient cells rescues HIV infectivity while reexpression of a LEDGF/p75 mutant
lacking the integrase binding domain (IBD) does not. (b) LEDGF/p75 reexpression in
LEDGF/p75 deficient cells rescues HIV infectivity while reexpression of a LEDGF/p75 mutant
lacking the chromatin binding domain made up by the PWWP and AT Hook motifs does not. (c)
Alu-PCR results. Reexpression of LEDGF/p75 rescues the number of integrates per cell. [4]
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Figure 6. LEDGF/p75 tethering model. LEDGF/p75 acts as a tether between viral integrase and
chromatin facilitating the integration of the viral DNA into the host genome [4].

15

Site selection for HIV-1 integration is not a random process; it is bias towards gene rich
sites rather than non-coding regions of DNA [35]. Lentiviruses such as HIV-1 greatly prefer
transcription units over gene-poor regions and integration occurs nearly equally along gene
lengths, and positively correlates with transcriptional activity [36]. HIV-1 integration site
distribution is altered in LEDGF/p75 deficient cells with more than half of the favoring of
transcription units being eliminated with the depletion of LEDGF/p75 [35]. These results suggest
that the frequency and distribution of HIV-1 integration is in large part governed via the
interaction between IN and cellular LEDGF/p75 [37].
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1.6.

Project Hypothesis
Our hypothesis is that evolutionary conserved regions of LEDGF/p75, rich in charged

residues, therefore solvent exposed, and predicted to harbor post-transcriptional modifications
may play an important role in the HIV-1 cofactor activity of LEDGF/p75. We propose that these
regions function by recruiting other cellular factors that facilitate HIV-1 integration (Fig. 7).

Figure 7. Newly proposed molecular mechanism of LEDGF/p75 in HIV-1 integration. Contrary
to the tethering model, this model proposes that LEDGF/p75 recruits other cellular factors that
allow integration to occur more efficiently.
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1.7.

Significance and Aims

Significance
HIV-1 integration is an obligated step in its life cycle, viral replication can only occur
after the formation of the provirus. LEDGF/p75 is a required cellular co-factor for HIV-1
integration [4]. Understanding the molecular mechanism of LEDGF/p75 in HIV-1 integration
will significantly contribute to the identification of new targets for anti-HIV-1 drug development.

Specific Aim 1: Generation of stable cell lines expressing LEDGF/p75 mutants.
Using different prediction software we identified seven main LEDGF/p75 evolutionarily
conserved regions which are rich in charged residues and that are targeted by different posttranslational modifications. Deletion mutants lacking these regions were generated by PCR
mutagenesis and stably expressed in LEDGF/p75-deficient human CD4+ T cells.

1.1 Selection of LEDGF/p75 regions to evaluate. Regions were chosen for evaluation based on
stringent selection criteria. (1) The regions must be evolutionarily conserved from amphibians to
humans. (2) They must contain clusters of charged residues. (3) These regions should serve as
potential targets of post-translational modifications. (4) Their role in HIV-1 infection is
unknown.

1.2 Stable expression of LEDGF/p75 mutants in LEDGF/p75-deficient human CD4+ T cells.
The HIV-1 co-factor activity of LEDGF/p75 was evaluated by re-expressing different deletion
mutants in LEDGF/p75-deficient CD4+ T cells (TL3 cells). These cells were generated by
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transduction with a lentiviral vector expressing an shRNA against LEDGF/p75. Using this
procedure, a 97% reduction of the LEDGF/p75 mRNA levels was permanently achieved [4].
HIV-1 infection is severely impaired in TL3 cells and infectivity is rescued by re-expression of
LEDGF/p75. Retroviral transduction was used to stably express the different LEDGF/p75
deletion mutants in TL3 cells.

Specific Aim 2: Evaluate the role of different LEDGF/p75 regions in HIV-1 infection.
TL3 cells stably expressing the different LEDGF/p75 deletion mutants were challenged
with replication defective HIV-1 luciferase viruses. Infectivity was evaluated five days later by
measuring luciferase activity in the challenged cells. As control, TL3 expressing no LEDGF/p75,
LEDGF/p75 wild type or mutants lacking the chromatin binding domain or the integrase binding
domain were used [38, 39] (Fig. 8).
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Figure 8. LEDGF/p75 chromatin binding and integrase binding domains. LEDGF/p75 interacts
with chromatin and integrase through its chromatin binding domain (CBD) and integrase binding
domain (IBD), respectively. The CBD is composed of the PWWP and two AT hook motifs.
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Specific Aim 3: Evaluate the influence of different LEDGF/p75 regions in the tethering
activity of LEDGF/p75.
The tethering activity of LEDGF/p75 depends on its simultaneous binding to chromatin
and integrase. Chromatin binding and integrase binding activities were evaluated for each of the
LEDGF/p75 deletion mutants.

3.1 To determine the effect of different mutations on the chromatin binding activity of
LEDGF/p75. Chromatin binding was assessed by the chromatin binding assay [39] that is based
on the resistance of chromatin-bound proteins to extraction in isotonic buffers containing 1%
Triton X-100. Whereas, the strength of chromatin binding was determined by the salt extraction
assay which is based on the capacity of increased ionic strengths to break down charged
interactions between proteins and DNA.

3.2 To determine the effect of different mutations on the integrase binding activity of
LEDGF/p75. Integrase binding activity was evaluated by the capacity of LEDGF/p75 mutants to
protect integrase from proteasome-mediated degradation [40]. In addition, integrase interaction
was further proved by co-immunoprecipitation techniques. Finally the combined capacity of
LEDGF/p75 mutants of chromatin and integrase binding activities (integrase to chromatin
tethering activity) was interrogated in LEDGF/p75-deficient cells expressing eGFP-tagged HIV1 integrase.
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Specific Aim 4: Evaluation of potential LEDGF/p75 protein-protein interactors through mass
spectrometry.
Data obtained from LEDGF/p75 deletion and point mutants suggested that other cellular
factors may interact with LEDGF/p75 and promote its HIV-1 co-factor activity. In order to
discover possible LEDGF/p75 protein-protein interactors we will perform a mass spectrometry
analysis of LEDGF/p75.

4.1 To conduct a mass spectrometry analysis of LEDGF/p75. Using cells deficient for
LEDGF/p75 and cells reexpressing LEDGF/p75 a chromatin bound protein fraction was
obtained and run out on an SDS-PAGE gel which was then silver stained and protein bands
excised. These bands were then subjected to mass spectrometry analysis.

4.2 To confirm potential protein-protein interactions. Once potential LEDGF/p75 proteinprotein interactors are elucidated, their association with LEDGF/p75 will be confirm through the
use of immunoprecipitation experiments.
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Chapter 2: Implication of Serine Residues 271, 273, and 275 in the Human
Immunodeficiency Virus Type 1 Cofactor Activity of Lens Epithelium-Derived Growth
Factor/p75

2.1

Introduction

The lens epithelium-derived growth factor/p75 (LEDGF/p75) is a cellular cofactor for HIV-1
DNA integration implicated in the efficiency and genomic location of the viral integration
process [4, 35, 37, 41, 42]. Cells lacking LEDGF/p75 showed a severe defect in HIV-1 infection
characterized by decreased levels of integrated viral DNA in the absence of other pre-integration
defects in the viral life cycle [4, 37]. In addition, in the absence of LEDGF/p75, HIV-1 DNA
integration occurred less frequently in active transcription units and more often in close
proximity to CpG islands [35, 37, 41]. These data indicated that LEDGF/p75 is an important
target for anti-HIV-1 drug development.
LEDGF/p75 is a ubiquitously expressed chromatin-bound protein evolutionarily
conserved from bony fishes to humans. The chromatin-binding domain of LEDGF/p75, located
in the N-terminal region of the protein, was identified by analysis of deletion mutants [39, 43].
LEDGF/p75 mutants lacking the evolutionarily conserved PWWP and two AT hook motifs
failed to bind to chromatin during both interphase and mitosis. However, chromatin binding of
mutants lacking only one of these protein regions was normal or minimally defective [39]. These
data indicated that LEDGF/p75 chromatin binding requires the functional interaction of the
PWWP domain and two AT hook motifs [39]. More recently, mutagenesis analysis of
evolutionarily conserved residues within the PWWP suggested that a hydrophobic cavity in this
protein domain has a fundamental role in the chromatin binding of LEDGF/p75 [44].
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Co-immunoprecipitation of HIV-1 integrase and LEDGF/p75 drove the interest of
retrovirologists to this cellular protein [33]. The interaction of LEDGF/p75 with HIV-1 integrase
has been extensively characterized in non-infected cells where integrase is expressed as a sole
protein by stable or transient plasmid transfection, and in in vitro systems using purified
recombinant proteins [45-48]. The interaction of LEDGF/p75 with integrase occurs through a Cterminal region called the integrase binding domain (IBD) [38, 49, 50]. The IBD was identified
by evaluating the interaction of HIV-1 integrase with LEDGF/p75 deletion mutants using
different cellular and biochemical assays. LEDGF/p75 tethers HIV-1 integrase to the host
chromatin [51, 52], protects integrase from proteosomal-mediated degradation [40], promotes
integrase multimerization [53], and enhances its enzymatic activity in in vitro integration assays
[54]. The molecular basis of this protein-protein interaction was further defined after x-ray
diffraction analysis of an IBD- integrase catalytic core domain complex [55, 56].
Although the molecular mechanism of the HIV-1 cofactor activity of LEDGF/p75 has not
been completely understood yet, it is well established that it requires its chromatin and integrase
binding activities [4, 37]. HIV-1 infection of LEDGF/p75-deficient cells was rescued upon reexpression of LEDGF/p75 wild type (WT) but not of deletion mutants lacking the chromatin- or
the integrase-binding domains [4]. These observations suggested that chromatin-bound
LEDGF/p75 could tether lentiviral pre-integration complexes to the host chromatin allowing
efficient viral integration [4]. This tethering model was also supported by the role of LEDGF/p75
in HIV-1 DNA integration site distribution [35, 37, 41].
In order to evaluate if LEDGF/p75 regions, not involved in the tethering mechanism, are
required for its HIV-1 cofactor activity, we studied a panel of deletion mutants. These mutants
lacked different protein regions that are evolutionarily conserved and predicted to be solvent
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exposed as well as harboring different protein post-translational modifications. HIV-1 cofactor
activity and integrase to chromatin tethering capacity were evaluated for each of these mutants.
Using this systematic approach, we have identified that the LEDGF/p75 serine residues 271, 273
and 275 are involved in its HIV-1 cofactor activity without influencing its integrase to chromatin
tethering activity. Our results indicate that, in addition to its tethering activity, other molecular
events seem to be implicated in the HIV-1 cofactor role of LEDGF/p75.
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2.2

Materials and Methods

Plasmids. LEDGF/p75 expression plasmids. pFLAG LEDGF/p75 was used for transient
expression experiments. This plasmid has a human cytomegalovirus immediate early gene
(CMV) promoter driving the transcription of a LEDGF/p75 cDNA containing seven synonymous
mutations

in

the

target

site

of

the

twenty-one

shRNA

1340

(AACGGCAACACGAAGAGGCAA, changed nucleotides are underlined) [51]. This shRNA is
present in all the LEDGF/p75-deficient cell lines used in this report. The LEDGF/p75 open
reading frame was PCR amplified and cloned BamHI / ApaI into pCMV-FLAG expression
plasmid, upstream of the FLAG sequence. pCMV-FLAG was derived from pCMV-Myc [51] by
substituting Myc by the FLAG tag epitope. Myc was removed ApaI / BglII and a DNA linker
containing the FLAG sequence flanked by ApaI / BglII sticky ends was inserted.
Stable expression of LEDGF/p75 WT or mutants was achieved by retroviral transduction.
LEDGF/p75 was expressed from the murine leukemia virus (MLV) expression plasmid pJZ308
[4]. LEDGF/p75 mutants were generated by PCR with the Phusion™ Site-Directed Mutagenesis
Kit (Finnzymes, Inc) using specific primers (primers sequence available upon request) and
following the manufacturer’s instructions. All the constructs described above were verified by
overlapping DNA sequencing of the complete LEDGF/p75 cDNA.
HIV-1 integrase expression plasmids. pHIN-eGFP-IRES-P is a CMV-driven HIV-1
integrase-eGFP expression plasmid that was used to generate stable cell lines expressing this
fusion protein. This plasmid was derived from pHIN [51] by substituting the Myc tag with eGFP
and introducing an internal ribosome entry site (IRES)-puromycin resistance gene (PAC)
cassette downstream to the eGFP open reading frame. The IRES-PAC cassette was PCR
amplified

from

pEFIRESP
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with

primers

5’-

TATAAGATCTAATTCACGCGTGGTACCTCTAG-3’

and

5’-

TATAAGATCTGGTCGTGCGCTCCTTTCGGTCG-3’ and then introduced into a unique BglII
site in pHINeGFP.
Retroviral vector plasmids. Plasmids used for production of retroviral vectors, pHIVluc,
JZluc, and pTSINcherry/p75 were previously described [4], pCMVΔR8.91 and pMD.G were a
gift of D. Trono.

Cell lines. LEDGF/p75-deficient cell lines. The human CD4+ T cell line -LEDGF/p75-deficient,
TL3 cells [4], were used for stable expression of LEDGF/p75 mutants. These cells were generated
by transduction of SupT1 cells with a HIV-derived vector expressing a shRNA against
LEDGF/p75. As control we used TC3 cells that were also derived by transduction of SupT1 cells
with a HIV-derived vector expressing a scrambled shRNA sequence [4]. TL3 cells express 97%
less LEDGF/p75 mRNA than TC3 cells as determined by real time PCR [4]. To generate TL3 cells
expressing different LEDGF/p75 mutants, cells were transduced with a MLV-derived vector
expressing the LEDGF/p75 mutants (pJZ-LEDGF-FLAG) and selected in G418 (600µg /ml) as
described previously [4]. Robust polyclonal G418-resistant cell lines were obtained and
characterized by immunoblotting with an anti-LEDGF (BD Transduction Laboratories, catalog
number 611714) or anti-FLAG monoclonal antibodies (Mabs) (Clone M2, Sigma). The
LEDGF/p75-deficient HEK293T-derived cell line si1340/1428 [51] was used for transient
expression of LEDGF/p75 proteins.
HIV-1 integrase cell lines. LEDGF/p75-deficient HEK293T cells expressing Myc-tagged
HIV-1 integrase (LH4 cells, [40]) were used to evaluate the capacity of the LEDGF/p75 mutants
to protect HIV-1 integrase from proteosomal-mediated degradation. In addition, 2LKD-IN-eGFP
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cells were used to evaluate the integrase to chromatin tethering capacity of LEDGF/p75 mutants.
These cells are LEDGF/p75-deficient HEK293T cells stably expressing HIV-1 integrase Cterminally tagged with eGFP. To generate 2LKD IN-eGFP cells, HEK293T cells were plated at
3x106 in a 75-cm2 flasks and calcium-phosphate transfected the next day with 20µg of the
expression plasmid pCMV-IN-eGFP-IRES-P linearized at the prokaryotic backbone. Stably
transfected cells were obtained after selection in the presence of puromycin (3µg/ml) and
integrase-eGFP expression was verified by immunoblotting with an anti-eGFP Mab and by
fluorescence-activated cell sorting (FACS) analysis. Subsequently, LEDGF/p75 deficiency was
achieved in these cells by transduction with an HIV-based lentiviral vector expressing a
LEDGF/p75-specific shRNA 1340 [4]. This lentiviral vector integrates into the host genome a
cassette containing in cis a U6 small nuclear RNA promoter that drives the expression of a
LEDGF/p75-specific shRNA and a CMV promoter directing the expression of a mCherry
fluorescent protein. This expression system allows selection of LEDGF/p75 knockdown cells
based on their mCherry fluorescence levels [4]. Knockdown levels of LEDGF/p75 were verified
further by immunoblotting with an anti-LEDGF Mab.
SupT1-derived cell lines were grown in RPMI1640 while HEK293T-derived cells were
grown in DMEM and both culture mediums were supplemented with 10% of heat-inactivated
fetal calf serum, 2mM L-glutamine and 1% penicillin/streptomycin.

Generation of retroviral vectors. Procedures previously described [4] were followed for the
production of the different retroviruses used here. Briefly, MLV-derived vectors were produced
in Phoenix A packaging cells by calcium-phosphate co-transfection of 15µg of pJZLEDGF/p75
wild type or pJZLEDGF/p75 mutants or pJZluc and 5µg of the Vesicular Stomatitis Virus
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glycoprotein G (VSV-G) expression plasmid, pMD.G. Forty-eight hrs after transfection, the viral
supernatants were harvested and concentrated by ultracentrifugation at 124,750g for two hrs on a
20% sucrose cushion. HIV-derived vectors expressing anti-LEDGF shRNA were produced by
calcium-phosphate co-transfection of HEK293T with 15µg of pTSINcherry/p75 [4], 15µg of
pCMVΔR8.91 and 5µg of pMD.G. The viral-containing supernatant was collected and
concentrated by ultracentrifugation as described above. Single-round infection, luciferaseexpressing HIV (HIVluc) was prepared by calcium-phosphate co-transfection of HEK293T cells
with 15µg of pHIVluc [4] and 5µg of pMD.G Viral supernatant was collected forty-eight after
transfection and aliquots stored at -80°C until use.

Single-round viral infectivity assay. TL3, TC3, and LEDGF/p75-expressing TL3 cells were plated
at 1x105 cells in 500µl of RPMI1640 culture medium in 24-well plates and infected with HIVluc
or MLVluc viral supernatants. Five days post-infection, cells were collected by centrifugation at
1000g for six mins and the pellet lysed in 100µl of PBS-1% Tween 20 for 15 mins on ice.
Cellular lysates were centrifuged at 22,000g for 2 mins and supernatant used for quantification of
luciferase activity. An aliquot of 20µl of the cellular lysate supernatant was mixed with 45µl of
substrate (Bright-Glow™ Luciferase Assay System, Promega) and luciferase activity was
quantified using a microplate luminometer.

Immunoblotting. Cellular lysates were resolved by SDS-PAGE and transferred overnight to
PVDF membranes at 100 mAmp at 4°C. Membranes were blocked in TBS containing 10% milk
for one hour and then incubated with the corresponding primary antibody diluted in TBS-5%
milk-0.05% Tween 20 (antibody dilution buffer). FLAG-tagged LEDGF/p75 was detected with
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anti-FLAG Mab (1/500, M2, Sigma), non-tagged LEDGF/p75 was detected with anti-LEDGF
Mab (1/250), Myc-tagged HIV-1 integrase was detected with anti-Myc Mab (1/500, clone 9E10,
Covance). As loading control, anti-alpha tubulin Mab (clone B-5-1-2, Sigma) was used at a
1/4000 dilution. Membranes were incubated overnight at 4°C with anti-FLAG, -LEDGF, and Myc Mabs whereas anti-alpha tubulin Mab were incubated for two hrs at 25°C. Primary
antibody-bound membranes were washed in TBS-0.1% Tween 20 and bound antibodies detected
with goat anti-mouse Igs-HRP (Sigma) diluted 1/2000 in antibody dilution buffer followed by
chemoluminescence detection.

Chromatin-Binding Assay.

Previously described procedures [39] were followed with minor

modifications. Figure 3 of reference [39] shows a validation experiment where multiple proteins
located in different cellular compartments were evaluated. Briefly, 18x106 TL3-derived cells
expressing different LEDGF/p75 mutants were washed in PBS and distributed in three aliquots
containing equal amount of cells. Two of the samples were lysed for 15 mins on ice in 100µl of
CSK I buffer (10mM Pipes pH6.8, 100mM NaCl, 1mM EDTA, 300mM sucrose, 1mM MgCl2,
1mM DTT, 0.5% Triton X-100) containing protease inhibitors (final concentration: leupeptine
2µg/ml, aprotinin 5µg/µl, PMSF 1mM, pepstatin A 1µg/ml). The third sample was lysed for 15
mins on ice in 100µl CSK I buffer supplemented with 350mM NaCl and protease inhibitors,
centrifuged at 22,000g for 3 mins at 4°C and supernatant saved for further analysis (total
fraction, T). Cells lysed in CSK I buffer were centrifuged at 1000g for 6 mins at 4°C and the
supernatant pooled (non-chromatin-bound fraction, S1). S1 supernatants were clarified further by
centrifugation at 22,000g for 3 mins and supernatant transfer to a fresh tube while pellets were
washed once in 200µl of CSK I buffer. One of these pellets was resuspended in CSK I 350mM

30

NaCl buffer and incubated on ice for 15 mins followed by centrifugation at 22,000g for 3 mins at
4°C and the supernatant was collected for further analysis (chromatin-bound fraction, P1). The
other pellet, obtained after cell lysis in CSK I, was resuspended in 100µl of CSK II buffer
supplemented with protease inhibitors, 4 units of turbo DNase (Ambion) and 11µl of 10X turbo
DNase reaction buffer. DNase treatment of this pellet was conducted at 37°C for 30 mins and
then followed by extraction with (NH4)2SO4 250mM for 15 mins at 37°C. The DNase/
(NH4)2SO4 treated sample was centrifuged at 22,000g for 3 mins and the supernatant saved for
analysis (chromatin-bound fraction, S2). The resulting pellet was further extracted with CSK I
350mM NaCl for 15 mins on ice, centrifuged at 22,000g for 3 mins and the obtained supernatant
(non-chromatin-bound fraction, P2) collected for analysis. A volume of 15.7µl of S1, P1, P2 and
T and 20µl of S2 (amounts equivalent to 0.9x106 cells) was evaluated by immunoblotting using
an anti-FLAG Mab.

Salt extraction assay. 36x106 TL3 cells or TL3 cells expressing LEDGF/p75 mutants were
washed with PBS and distributed in six samples, each containing an equal amount of cells. One
of the samples was resuspended in 100µl of Laemmli sample buffer, boiled for 9 mins and
centrifuged at 22,000g for 3 mins and the resulting supernatant was further analyzed (total
fraction, T). The other five cellular aliquots were lysed on ice for 15 mins in 100µl of CSK I
containing protease inhibitors and supplemented with increasing concentrations of NaCl (final
concentration: 100, 150, 200, 350 and 500mM). Lysed cells were centrifuged at 22,000g for 3
mins at 4°C and the supernatant (salt-extracted fraction) collected for analysis. The obtained
pellets (salt-resistant fraction) were subsequently boiled in 100µl of Laemmli sample buffer,
centrifuged at 22,000g for 3 mins at 4°C and the resulting supernatant collected. The presence of
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LEDGF/p75 in the total, salt-extracted or salt-resistant fractions was analyzed by
immunoblotting with an anti-FLAG Mab using 20µl of cell lysate, an equivalent amount of
6x104 cells.

Immunoprecipitation. The interaction of the LEDGF/p75 ΔCR3 mutant with Myc-tagged HIV1 integrase was evaluated by immunoprecipitation in the LEDGF/p75-deficient HEK293Tderived cell line si1340/1428 [40]. Cells were plated at 0.45X106 cells/well in a 6-well plate and
co-transfected the next day by calcium-phosphate with 2µg of pFLAG-LEDGF/p75 ΔCR3, or
pFLAG-LEDGF/p75 WT or pFLAG-LEDGF/p75 ΔIBD and 2µg of the HIV-1 integrase
expression plasmid pHIN. Forty-eight hrs after transfection, cells were lysed in 300µl of RIPA
buffer (150mM Tris-HCl, pH 8.0, 150mM NaCl, 0.5% DOC, 0.1% SDS, 1% NP-40)
supplemented with protease inhibitors. Cell lysates were clarified by centrifugation at 22,000g
for 3 mins and supernatant used for immunoprecipitation using goat anti mouse Igs-coated
magnetic beads (Pierce). Beads (100µl) were previously incubated for 20 mins on ice with 3µg
of anti-FLAG Mab diluted in RIPA buffer. Then, beads were separated from the unbound
antibodies, mixed with the cell lysate and rotated for 3hrs at 4°C. After this incubation, beads
were washed three times in RIPA buffer and bound proteins eluted by boiling in 30µl of
Laemmli sample buffer. Immunoprecipitated proteins were analyzed for the presence of Myctagged HIV-1 integrase and LEDGF/p75-FLAG by immunoblotting with anti-Myc and antiFLAG Mabs, respectively.

Integrase protection assay. LEDGF/p75-deficient HEK293T cells expressing Myc-tagged HIV1 integrase were used to evaluate the effect of different LEDGF/p75 deletion mutants on
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integrase protein stability. This assay is based on the integrase binding-dependent capability of
LEDGF/p75 to protect integrase from proteasome-mediated degradation [40]. Integrase protein
levels in these LEDGF/p75-deficient cells are very low, as detected by sensitive
immunoblottings, and re-expression of LEDGF/p75 WT rescues integrase levels ([40] and
figures 1b and 6a-I in this report). Cells were plated at 0.45x106 per well in a 6-well plate and
transfected the next day by calcium-phosphate with 2µg of pFLAG-LEDGF/p75 WT or mutants.
Forty-eight hrs after transfection, cells were lysed in 300µl of RIPA buffer supplemented with
protease inhibitors. Cell lysates were clarified by centrifugation at 22,000g for 3 mins and
supernatant used for immunoblotting with anti-Myc or anti-FLAG Mabs.

Integrase to chromatin tethering assay. This assay is based on the role of LEDGF/p75 in the
chromatin tethering of HIV-1 integrase [51]. Chromatin-bound LEDGF/p75 interacts with
integrase through the IBD, tethering the viral enzyme to chromatin during all the phases of the
cell cycle.

In LEDGF/p75-deficient cells, HIV-1 integrase lacks its exclusively nuclear

localization during interphase and is not associated to chromatin during mitosis ([51] and figure
7 in this report). 2LKD-IN-eGFP cells, lacking LEDGF/p75 and stably expressing HIV-1
integrase-eGFP, were used in this assay. Cells were plated at 2x105 in 2 mls of culture medium
in a LabTek II chambered coverglasses and transfected the next day with 2µg of pFLAGLEDGF/p75 wild type or mutants. Eighteen hrs after transfection, fresh culture medium was
added and forty-eight hrs later cells were washed three times in PBS and fixed with 4%
formaldehyde-PBS for 10 mins at 37°C. Then, cells were washed twice in PBS and stained with
DAPI. The subcellular distribution of HIV-1 IN-eGFP-LEDGF/p75 complex was analyzed by
fluorescence microscopy.
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HIV-1 DNA integration analysis. Viral integration was quantified by detection of Alu-LTR and
total HIV-1 cDNA by real-time PCR in TL3 and TL3 cells engineered to express LEDGF/p75 WT
or S271A/S273A/S275A mutant. Two completely independent experiments using two different
viral preparations were considered. In these experiments, 105 cells were infected with DNasetreated HΔEluc viral supernatant and cultured for ten days. Then DNA was extracted (High pure
PCR template preparation kit, Roche) from 106 infected cells and 20ng of DNA were used for
the detection of total HIV-1 cDNA, mitochondrial DNA and 2LTR circles while 0.2ng of DNA
were used for the Alu-LTR junctions PCR. Alu-LTR and total HIV-1 cDNA products were
normalized for mitochondrial DNA and 2LTR circles, respectively. All these real time PCRs
were performed in a MiniOpticon system (Bio-rad) with primers and conditions previously
described [4]. Fold change was calculated using the ∆Ct method as recommended in the thermocycler manual and differences were expressed in percentage, considering the value for TL3
LEDGF/p75 WT cells as 100%.

In silico analysis. Mutations introduced in LEDGF/p75 were guided by a systematic
bioinformatics analysis focused on evolutionarily conservation across different species, the
presence of post-translational modifications as well as the prediction of solvent accessibility.
Evolutionary conservation, as referred in this text, includes the presence of either identical or
homologous residues in the compared protein sequences. LEDGF/p75 protein sequences were
retrieved from the NCBI protein database and aligned using ClustalW2 [57], sequence
comparisons were performed with BLASTP 2.2.19+ [58]. LEDGF/p75 protein motif search was
performed with the ELM server [59] and the prediction of relative solvent accessibility with
PaleAle [60].
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2.3

Results

Experimental strategy. Two regions of LEDGF/p75, the chromatin-binding domain and the
IBD, are required for its HIV-1 cofactor activity [4, 37]. However, the involvement of other
LEDGF/p75 regions in HIV-1 infection has not been previously studied. In order to evaluate if
LEDGF/p75 protein regions not implicated in chromatin binding or integrase interaction are also
necessary for HIV-1 infection, a panel of deletion mutants was analyzed. These mutants were
stably expressed in a LEDGF/p75-deficient human CD4+ T cell line (TL3 cells) [4] and their
ability to rescue HIV-1 infection was evaluated. In addition, the chromatin- and integrasebinding activities of these mutants were assessed.
Although analysis of LEDGF/p75 deletion mutants have been used before to successfully
map functional domains in LEDGF/p75 [38, 39, 43, 49, 61], this approach could lead to
misinterpretations due to the global impact of mutations on the structure, hence the function, of
the analyzed protein. In order to prevent data over-interpretation, only deletion mutants causing a
decrease in the HIV-1 cofactor activity of LEDGF/p75 similar to that observed following
deletion of the chromatin-binding or the integrase-binding domains were considered for further
analysis. Finally, the phenotypes observed in deletion mutants were verified in LEDGF/p75 point
mutants.
In order to facilitate the analysis of LEDGF/p75 mutants, a C-terminally FLAG tagged
LEDGF/p75 was used. To exclude any artifactual observation due to the addition of this small
tag to LEDGF/p75, tagged (WT-FLAG) and not tagged (WT) versions of this protein were
evaluated for their interaction with chromatin and HIV-1 integrase and for their HIV-1 cofactor
activity (Fig. 9).
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The effect of this tag on the chromatin binding strength of LEDGF/p75 was evaluated
using the chromatin salt extraction assay. This is based on the effect of increased salt
concentrations on the binding of proteins to chromatin. TL3 cells expressing LEDGF/p75 WT or
WT-FLAG were lysed in 1% Triton X-100 CSK I buffer containing increasing concentrations of
NaCl (100, 150, 200, 350 and 500mM). Cellular lysates were centrifuged and supernatant (saltextracted fraction) and pellet (salt-resistant fraction) were evaluated by immunoblotting for the
presence of LEDGF/p75. Total LEDGF/p75 extraction was achieved by lysing unfractionated
cells in Laemmli sample buffer (Fig. 9a). Using this method, we found that both LEDGF/p75
forms persisted bound to chromatin (salt-resistant fraction) at 100 and 150mM NaCl and were
fully extracted above 200mM NaCl (Fig. 9a), indicating that the FLAG tag did not affect its
binding to chromatin.
To evaluate the effect of the FLAG tag on the interaction of LEDGF/p75 with HIV-1
integrase we compared the ability of LEDGF/p75 WT and WT-FLAG to protect integrase from
proteasome-mediated degradation (integrase protection assay) (Fig. 9b). LEDGF/p75-deficient
HEK293T cells, stably expressing Myc-tagged HIV-1 integrase, LH4 cells, were transiently
transfected with plasmids expressing LEDGF/p75 WT, WT-FLAG or ΔIBD and integrase
protein levels were evaluated by immunoblot forty-eight hrs after transfection. Steady-state HIV1 integrase levels were very low in the absence of LEDGF/p75 and dramatically increased upon
expression of LEDGF/p75 WT or WT-FLAG but not of the ΔIBD mutant (Fig. 9b), indicating
that the FLAG tag did not affect the interaction of LEDGF/p75 with HIV-1 integrase.
The influence of the FLAG tag on the direct interaction of LEDGF/p75 with HIV-1
integrase was also evaluated by co-immunoprecipitation. LEDGF/p75-deficient HEK293T cells
co-expressing LEDGF/p75 WT, WT-FLAG or ΔIBD-FLAG and Myc-tagged HIV-1 integrase
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were lysed and immunoprecipitated with an anti-LEDGF/p75 Mab. Then, the presence of
integrase and LEDGF/p75 was evaluated in the immunoprecipitated proteins by immunoblotting
with anti-Myc or anti-LEDGF/p75 Mabs, respectively. In support of data in figure 1b, both
LEDGF/p75 WT and WT-FLAG very efficiently immunoprecipitated HIV-1 integrase, while
LEDGF/p75 ΔIBD did not (Fig. 9c). These data also demonstrated that the FLAG tag on
LEDGF/p75 did not affect its interaction with HIV-1 integrase.
Finally, we compared the HIV-1 co-factor activity of LEDGF/p75 WT and WT-FLAG.
TL3 cells stably expressing or not each of these LEDGF/p75 proteins were infected with HIV luc
and five days after infection luciferase levels were detected (Fig. 9d). In correlation with
observations described in figure 9a to 9c, the C-terminal FLAG did not alter the LEDGF/p75
HIV cofactor activity.
In summary, data in figure 9 clearly demonstrated that LEDGF/p75 WT-FLAG is
functionally equivalent to its non-modified variant and, unless it is specified, all the data
described below were obtained with LEDGF/p75 FLAG tagged at the C-terminus.
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Figure 9. (a) Salt extraction assay. TL3 cells expressing the LEDGF/p75 WT or WT-FLAG
were lysed in a buffer containing increasing NaCl concentrations. Cells were separated into a
soluble fraction and an insoluble fraction by centrifugation, and the presence of LEDGF/p75 was
evaluated by immunoblotting with an anti-LEDGF or anti-FLAG MAb, as indicated. An
unfractionated total cellular fraction (T) was included as a control. (b) Integrase protection assay.
LEDGF/p75-deficient HEK293T cells stably expressing Myc-tagged HIV-1 integrase were
either transiently transfected or not transfected with plasmids expressing the LEDGF/p75 WT,
WT-FLAG, or _IBD-FLAG. Expression levels of LEDGF/p75 proteins and HIV-1 integrase
were determined by immunoblotting with anti-LEDGF and anti-Myc MAbs, respectively. (c)
Coimmunoprecipitation of HIV-1 integrase with LEDGF/p75. LEDGF/p75-deficient HEK293T
cells were cotransfected with plasmids expressing the LEDGF/p75 WT, WT-FLAG, or _IBDFLAG and Myc-tagged HIV-1 integrase and subjected to immunoprecipitation with an antiLEDGF MAb. Immunoprecipitated proteins were detected by immunoblotting with anti-Myc or
anti-LEDGF MAbs. Mouse antibody heavy and light chains were used as a loading control for
the immunoprecipitation. LEDGF/p75 and HIV integrase proteins were detected in the samples
used for immunoprecipitation (input) by immunoblotting with anti-LEDGF and anti-Myc MAbs,
respectively. (d) Single-round infection of TL3 cells expressing the LEDGF/p75 WT or WTFLAG. Cells were challenged with HIVluc, and luciferase activity was analyzed 5 days later.
Luciferase levels detected in TL3 cells expressing the LEDGF/p75 WT were considered to be
100%. Error bars indicate standard deviation values calculated for a number (n) of independent
infection experiments performed on different days with different viral preparations.
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LEDGF/p75 deletion mutants. Regions deleted from LEDGF/p75 are schematized in figure
10a. These regions were designated conserved/charged regions (CR) 1, 2, 3, 4 and 5. Region
boundaries were established based on evolutionary conservation of LEDGF/p75 across different
species, the presence of predicted or demonstrated post-translational modifications and the
existence of clusters of polar residues that directly correlate with protein solvent accessibility.
The CR1 region contains 52 amino acids and was selected based on its evolutionary
conservation in mammals and on its proposed role in the LEDGF/p75 PWWP domain chromatin
binding activity [39]. This region is enriched for charged amino acids (54.8%) and 76.4% of
them are identical or homologous residues (conserved) present from avian to humans (Data not
shown). Interestingly, CR1 contains a cluster of eight Ser/Thr phosphosites between residues
105-135 [62-67], this cluster represents 36.3% of the total identified phosphorylated Ser/Thr
residues in LEDGF/p75. In addition, Thr141 has been found phosphorylated both in human and
mouse cells [62, 63, 67]. This phosphosite is contained in a predicted forkhead-associated
domain (FHA) interaction motif, LEDGF/p75 residues 141-144. The FHA domain is a protein
module present in prokaryotic and eukaryotic proteins involved in signaling, cell cycle control
and DNA repair that binds to specific threonine phosphoporylated sequences [59].
CR2 and CR3 boundaries were previously described [39]. These regions were
demonstrated to cooperate with the PWWP domain and AT hook motifs during LEDGF/p75
chromatin binding [39]. The CR2 region is 68 amino acids long, 58.8% are charged and 67% are
conserved from amphibians to humans (Data not shown). Evolutionary conservation and solvent
exposure is particularly interesting within residues 212-249 where 68% are present in bony
fishes and 70.3% of them are charged and predicted to be exposed to the solvent [60]. In
addition, although CR2 represents only 12.8% of LEDGF/p75, it contains 29.4% of its lysine
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residues. Lysine is targeted by different post-translational modifications including methylation,
SUMOylation, ubiquitination and glycosylation.
The CR3 region is 59 amino acids long and 64% of these residues are charged (Data not
shown). The N-terminal region of CR3, residues 267-275, contains six demonstrated
phosphorylated Ser/Thr sites which represent 27.2% of the LEDGF/p75 Ser/Thr identified
phosphosites [64-71]. These Ser/Thr residues are predicted to be targeted by protein kinase
casein kinase 2 [59]. In addition, residues 271-275, contain two phosphorylated serines that are
conserved from bony fishes to humans. An evolutionarily conserved cluster of acidic residues
follows these phosphosites.
The C-terminal part of LEDGF/p75 contains the IBD. N-terminally to this domain, a
region 14 amino acids long, that is rich in conserved and charged residues was deleted for
analysis (CR4 region). In addition, a region 88 amino acids long, designated CR5, that is located
C-terminally to the IBD was also independently deleted. Although 70% of the residues in CR5
are evolutionarily conserved, this region is not rich in charged amino acids. However, CR5
contains four demonstrated Ser/Thr phosphosites [67] and three of them are clustered in its Cterminal end.

Role of different protein regions of LEDGF/p75 in HIV-1 infection. TL3 cells were used to
evaluate the role of different LEDGF/p75 protein regions in HIV-1 infection. Deletion mutants
were stably expressed by retroviral transduction of TL3 cells. Similar levels of re-expressed
LEDGF/p75 proteins of the expected relative molecular weight were verified by immunoblotting
with anti-LEDGF/p75 and anti-FLAG Mabs (Fig. 10b). Non FLAG-tagged LEDGF/p75 ΔIBD
was detected only with an anti-LEDGF/p75 Mab, while FLAG-tagged LEDGF/p75 ΔCR2,
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lacking the epitope detected by the anti-LEDGF/p75 Mab, was only detected by the anti-FLAG
antibody. The LEDGF/p75 ΔCR5 mutant failed to be expressed in TL3 cells, although robust
polyclonal G418-resistant cell lines were obtained after two independent attempts. In addition,
treatment of these cell lines with the proteasome inhibitor MG132 did not rescue the expression
of LEDGF/p75 ΔCR5 (Data not shown), therefore we excluded this region from further analysis.
TL3-derived cell lines expressing LEDGF/p75 deletion mutants were challenged with
HIVluc [4] and five days later luciferase activity was measured (Fig. 10c). Standard deviations
and the number of independent experiments performed are indicated. Luciferase levels detected
in TL3 cells expressing LEDGF/p75 WT were considered as 100% infectivity.
Re-expression of FLAG-tagged LEDGF/p75 WT rescued infectivity in these cells as
previously reported for a non-tagged LEDGF/p75 [4]. In addition, LEDGF/p75 lacking the IBD,
the PWWP domain (P), or the PWWP domain and the AT hook motifs (P/AT) exhibited 12.3%,
63.4%, and 32.9% of the HIV-1 cofactor activity of LEDGF/p75 WT, respectively. These data
were also in agreement with previous observations [4, 37]. Interestingly, the deletion of CR2 or
CR4 only slightly impaired the cofactor activity of LEDGF/p75 showing 90.5% and 76% of the
wild type activity, respectively. On the contrary, deletion of CR1 reduced the cofactor activity to
41% while deletion of CR3 caused a larger defect exhibiting only 32.4% of the wild type
activity. Importantly, the reduction in cofactor activity observed after deleting CR3 was
comparable to the simultaneous deletion of PWWP and AT hooks (Fig. 10c).
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Figure 10. Evaluation of the HIV-1 cofactor activities of LEDGF/p75 deletion mutants. (a)
Schematic representation of deleted regions. (b) Different LEDGF/p75 deletion mutants were
stably expressed in LEDGF/p75 knockdown TL3 cells, and their protein levels were evaluated
by immunoblotting using anti-LEDGF or anti-FLAG MAbs. Alpha-tubulin detection was used as
a loading control. P and P/A represents PWWP and PWWP/AT hook, respectively. (c) Singleround HIV-1 infections of TL3-derived cells. Cells immunoblotted in b were challenged with
HIVluc, and luciferase activity was determined 5 days later.
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In order to evaluate further the role of the CR3 region of LEDGF/p75 in HIV-1 infection,
we generated three smaller deletion mutants within this region (Fig. 11a). The boundaries of the
new deletion mutants were established considering the sequence aspects described previously. A
group of positively charged amino acids conserved from avian to humans was considered to limit
CR3.1 whereas CR3.2 was defined by the presence of two clusters of charged and conserved
residues. CR3.3 is a deletion within CR3.2 containing the C-terminal cluster of conserved and
charged residues present in CR3.2. (Fig. 11a). LEDGF/p75 proteins lacking CR3.1, CR3.2 and
CR3.3 regions were expressed in TL3 cells (Fig. 11b) and their HIV-1 cofactor activity evaluated
(Fig. 11d). Although, deletion of CR3.2 and CR3.3 showed 86.9% and 64.7% of the LEDGF/p75
WT cofactor activity, respectively, CR3.1 deletion decreased the activity of LEDGF/p75 to
27.3% of that observed in the wild type protein. These data suggest that LEDGF/p75 residues
267-281 have a role in HIV-1 infection.

Role of Ser 271, 273 and 275 in HIV-1 infection. Serine residues 271, 273, 275 in LEDGF/p75
have been reported to be phosphosites in global phosphoproteomics analysis of human and
mouse cells [64-71]. In addition, these residues are predicted to be targeted by protein kinase
casein kinase 2 (PKCK2) [59], an enzyme that phosphorylates serine/threonine residues that are
followed by an acidic residue in position +3 from the C-terminus of the phosphate acceptor [72].
In order to evaluate the role of serine residues 271, 273, 275 in HIV-1 infection, LEDGF/p75
mutants S271A/S273A/S275A, S271A, S273A and S275A were stably expressed in TL3 cells
(Fig. 11c) and HIV-1 infectivity evaluated (Fig. 11d). Immunoblot analysis of transduced TL3
cells demonstrated similar levels of the re-expressed LEDGF/p75 mutants as compared to cells
expressing the wild type protein (Fig. 11c). However, the HIV-1 cofactor activity of LEDGF/p75
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S271A/S273A/S275A was only 41.5% of the activity of the wild type protein, indicating the
relevance of these phosphosites. These results were confirmed by evaluating two independently
derived TL3 cell lines expressing LEDGF/p75 S271A/S273A/S275A in ten independent infection
experiments with HIVluc. Although HIV-1 infection was reduced in TL3 LEDGF/p75
S271A/S273A/S275A cells, its susceptibility to infection by a murine leukemia virus (MLV)derived vector expressing luciferase was not altered as compared to parental cells (Data not
shown). Since LEDGF/p75 is not required for MLV infection [4, 37], these data further
confirmed the specificity of the observed effect, indicating that the reduced susceptibility to
HIV-1 infection was not due to a global defect present in these two independently derived cell
lines expressing LEDGF/p75 S271A/S273A/S275A.
Acidic residues in positions -1, +1, +2, +4 and +5, relative to the phosphate acceptor site,
are present in most of the physiological substrates of PKCK2 [72]. Additional acidic residues are
found at position +5 of Ser 271, +1, +4 and +5 of Ser 273 and positions -1, +1, +2, and +5 of Ser
275. This analysis predicts Ser 275 as a better substrate of PKCK2 than Ser 271 or Ser 273. To
establish the implication of each of these residues in HIV-1 infection, TL3 cells expressing
LEDGF/p75 single point mutants S271A, S273A, or S275A were developed (Fig. 11c) and
challenged with HIVluc. As shown in figure 11d, individual Ser to Ala mutations of these
residues did not have any effect on the viral cofactor activity of LEDGF/p75, exhibiting from
82.6% to 96.9% of the wild type activity.
In all the HIV infection experiments described above (Figs. 10c and 11d), the
LEDGF/p75 ΔCR3 and S271A/S273A/S275A mutants expressed in TL3 cells were FLAG tagged
at their C-terminus. Although we demonstrated that FLAG did not affect the HIV cofactor
activity of LEDGF/p75 WT (Fig. 9d); we also evaluated the role of non-tagged versions of
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LEDGF/p75 S271A/S273A/S275A, ΔCR3 and ΔPWWP/ΔAT mutants in HIV infection. TL3
cells expressing non-tagged LEDGF/p75 WT or mutants (Fig. 11e) were challenged with HIVluc
and five days later luciferase was determined. As expected, a similar impairment in the HIV
cofactor activity of LEDGF/p75 was observed in these mutants regardless of the presence or
absence of the FLAG tag (Fig. 11f).
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Figure 11. HIV-1 cofactor activity of different LEDGF/p75 CR3 mutants. (a) Analysis of
charged residues in CR3 used to establish the boundaries of CR3.1, CR3.2, and CR3.3. (b and c)
Expression of LEDGF/p75 mutants in TL3 cells evaluated by immunoblotting with an antiFLAG MAb. Alpha-tubulin detection was used as a loading control. (d) Single-round infection
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of TL3 cells expressing LEDGF/p75 mutants. Cells evaluated in b and c were challenged with
HIV-1 luciferase reporter viruses, and luciferase activity was analyzed 5 days later. Infectivity
and error bars were calculated as described in the legend of Fig. 1d. (e) Immunoblotting
detection of the reexpressed LEDGF/p75 WT and mutants in TL3 cells using an anti-LEDGF
MAb. Detection of endogenous LEDGF/p52 was used as a loading control. (f) Single-round
infection of TL3 cells expressing the nontagged LEDGF/p75 WT or mutants. Cells
immunoblotted in e were challenged with HIVluc, and luciferase activity was analyzed 5 days
later. Infectivity and error bars were calculated as described in the legend of Fig. 9d.
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HIV-1 integration in TL3 cells expressing LEDGF/p75 S271A/S273A/S275A. A role of
LEDGF/p75 in HIV-1 DNA integration has been clearly established [4]. In order to evaluate if
the LEDGF/p75 motif S271/S273/S275 was involved in viral integration, TL3 cells expressing or
not LEDGF/p75 WT or the S271A/S273A/S275A mutant were infected with HIVluc and ten
days later analyzed. Two completely independent experiments using two different viral
preparations were analyzed. DNA was isolated from infected cells and Alu-LTR junctions,
mitochondrial DNA, HIV gag DNA (total HIV DNA) and HIV 2LTR circles were quantified by
real time PCR. Levels of Alu-LTR junctions were normalized to mitochondrial DNA to ensure
that equal cell numbers were analyzed.
As previously reported, Alu-LTR levels were decreased in TL3 cells as compared to TL3
cells expressing LEDGF/p75 WT, indicating that HIV-1 DNA integration is defective in the
absence of LEDGF/p75 (Fig. 12). Importantly, TL3 cells expressing LEDGF/p75
S271A/S273A/S275A were also defective for viral integration and the integration levels
correlated in some extension with the degree of impairment in its co-factor activity shown in
figures 11d and 11f.
In order to estimate HIV-1 integration by an alternative approach, total HIV DNA (gag
DNA) was determined in these cells ten days post-infection. Since infected cells passed several
generations before analysis, it is expected that only HIV DNA integrated forms will persist and
gag DNA will be a good indicator of viral integration. Nevertheless, to exclude the possibility of
detecting also remnants of

non-integrated forms of the viral genome, the levels of total HIV

DNA were normalized to levels of HIV 2LTR circles. Importantly, similar 2LTR levels were
detected in the different infected cell lines at the time of analysis (Data not shown). Results in
figure 12 shown that total HIV DNA was also reduced in infected TL3 LEDGF/p75
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S271A/S273A/S275A cells as compared to cells expressing the wild type protein, indicating that
HIV DNA integration is defective in TL3 cells expressing this LEDGF/p75 mutant.
Importantly, the total HIV DNA levels in the analyzed cells correlated better with their
susceptibility to infection than the levels of Alu-LTR junctions; compare data in figures 11d and
12. These results suggested that HIV-1 DNA integration in genomic regions distant from Alu
sequences was also impaired in TL3 and TL3 LEDGF/p75 S271A/S273A/S275A cells.
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Figure 12. HIV-1 DNA integration in TL3 cells expressing LEDGF/p75 S271A/S273A/S275A.
Results from two independent experiments using different viral preparations are represented.
DNA products were quantified by real time PCR ten days after infection. Bars represent (a) AluLTR DNA levels after normalization to mitochondrial DNA and in (b) total HIV DNA after
normalization to 2LTR circles DNA. Normalized levels of Alu-LTR and total HIV DNA
detected in TL3 LEDGF/p75 WT cells were considered as 100%.
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Chromatin-binding activity of LEDGF/p75 mutants. It has been proposed that LEDGF/p75
acts as a molecular tether that links the pre-integration complex-associated integrase to the host
chromatin [41, 51]. According to the tethering model, two functional LEDGF/p75 regions, the
chromatin-binding domain and the IBD, are required for HIV-1 integration [4]. In order to
correlate the HIV-1 cofactor activity of LEDGF/p75 CR mutants with their tethering capacity,
we evaluated their chromatin binding and integrase interaction activities.
Chromatin-binding was evaluated using the previously reported chromatin-binding assay with
minor modifications [39] (Fig. 13a). This procedure is based on the resistance of chromatinbound proteins to be extracted with isotonic buffers (i.e. CSK I buffer) containing 1% TritonX100. In agreement with previous observations [39, 44], LEDGF/p75 persisted bound to the
chromatin fraction (P1 fraction) after cellular lysis in 1% Triton-X100 CSK I buffer and it was
only released from this compartment by DNase and 250mM (NH4)2SO4 treatment (S2 fraction)
(Fig. 13a). However, a LEDGF/p75 mutant lacking the chromatin-binding domains,
ΔPWWP/ΔAT, was fully extracted by 1% Triton-X100 CSK I buffer (S1 fraction) (Fig. 13a).
This assay revealed that all four LEDGF/p75 deletion mutants and LEDGF/p75
S271A/S273A/S275A were exclusively distributed to the chromatin-bound fractions (P1 and S2
fractions) as the wild type LEDGF/p75 protein (Fig. 13a). Importantly, although the HIV-1
cofactor activity of LEDGF/p75 ΔCR3 or LEDGF/p75 S271A/S273A/S275A was impaired (Fig.
10c and 11d), the chromatin-binding activity of these mutants was unaffected. These results
excluded defective chromatin binding as the cause for a deficient cofactor activity in these
LEDGF/p75 mutants.
Although the CR-deleted LEDGF/p75 mutants are chromatin-bound, we evaluate the
strength of their binding by the salt extraction method described in figure 9a. Using this method,
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we found that LEDGF/p75 WT persisted bound to chromatin (salt-resistant fraction) at 100 and
150mM NaCl and was fully extracted above 200mM NaCl (Figs. 9a and 13b). Contrary to this, a
mutant lacking the PWWP domain was partially extracted at 100mM and fully extracted above
150mM NaCl (Data not shown) whereas LEDGF/p75 ΔPWWP/ΔAT, that failed to bind to
chromatin, was fully extracted at 100mM NaCl (Fig. 13b). Therefore, the strength of chromatin
binding determined for LEDGF/p75 WT and ΔPWWP/ΔAT by the salt extraction method
perfectly correlated with their chromatin-binding activity observed with the previously described
chromatin-binding assay (Fig. 13a).
The strength of chromatin binding of the different LEDGF/p75 CR deletion mutants was
then evaluated by the salt extraction method. As shown in figure 13b, deletion of CR1 or CR3
did not affect the LEDGF/p75 chromatin binding strength since these mutant proteins were only
fully extracted above 200mM NaCl. In contrast to these results, deletion of CR2 and CR4
slightly decreased LEDGF/p75 resistance to salt extraction evidenced by partial extraction of
these mutants at 150mM NaCl (Fig. 13b). These data suggested that the CR2 and CR4 regions
contribute to the number of charged interactions between LEDGF/p75 and chromatin. In
addition, these results correlated with a previous report indicating a contribution of CR2 and the
C-terminal region of LEDGF/p75 to chromatin binding [39].
Similarly to LEDGF/p75 ΔCR3, the strength of chromatin binding of LEDGF/p75
S271A/S273A/S275A was indistinguishable from the wild type protein (Fig. 13b). These results,
together with the wild type phenotype observed for these mutants in the chromatin-binding assay
(Fig. 13a), strongly indicated that their defective HIV-1 cofactor activity cannot be ascribed to an
impaired chromatin-binding capacity.
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Figure 13. Chromatin-binding activity of LEDGF/p75 mutants. (a) Chromatin-binding assay.
TL3 cells expressing different LEDGF/p75 mutants were fractionated into non-chromatin-bound
fractions (S1 and P2) and chromatin-bound fractions (P1 and S2) and the presence of
LEDGF/p75 in these fractions was evaluated by immunoblot with an anti-FLAG Mab. An
unfractionated total cellular fraction (T) was included as control. (b) Salt extraction analysis of
LEDGF/p75 mutants stably expressed in TL3 cells. The salt concentration that extracted
LEDGF/p75 WT from chromatin is marked with a rectangle.
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Interaction of LEDGF/p75 mutants with HIV-1 integrase. In order to analyze the functional
interaction of LEDGF/p75 mutants with HIV-1 integrase, we evaluated their capacity to shield
integrase from degradation (integrase protection assay, fig. 14). LEDGF/p75-deficient HEK293T
cells, stably expressing Myc-tagged HIV-1 integrase, were transiently transfected with plasmids
expressing LEDGF/p75 WT or mutants and integrase protein levels were evaluated by
immunoblot forty-eight hrs later.
Steady-state HIV-1 integrase levels were very low in the absence of LEDGF/p75 and
dramatically increased upon expression of LEDGF/p75 WT but not of LEDGF/p75 ΔIBD (Figs.
14a-I and 9b), as previously reported [40]. Using this reporter system, we evaluated the
interaction of the different LEDGF/p75 deletion mutants with HIV-1 integrase. Significantly,
expression of the different LEDGF/p75 CR deletion mutants (Fig. 14a-II) and of the LEDGF/p75
S271A/S273A/S275A mutant (Data not shown) prevented integrase degradation in LH4 cells.
The levels of rescued integrase mirrored those of re-expressed LEDGF/p75 proteins; indicating
that these mutations did not affect the capacity of LEDGF/p75 to interact with the viral protein.
In addition, these data confirmed previous observations showing that the IBD was necessary and
sufficient to protect integrase from degradation [40]. Furthermore, these findings clearly
indicated that the reduced cofactor activity observed in LEDGF/p75 ΔCR3 or the triple point
mutant LEDGF/p75 S271A/S273A/S275A was not due to a defective interaction with HIV-1
integrase.
In order to evaluate directly the interaction of LEDGF/p75 ΔCR3 with HIV-1 integrase,
we performed a co-immunoprecipitation experiment (Fig. 14b). LEDGF/p75 WT, or ΔCR3 or
ΔIBD were transiently co-expressed with Myc-tagged HIV-1 integrase in LEDGF/p75knockdown HEK293T cells, si1340/1428 cells [51]. Forty-eight hrs later, cells were lysed in
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RIPA buffer and incubated with anti-mouse Igs-coated magnetic beads loaded with anti-FLAG
Mab. Immunoprecipitated proteins were later evaluated for the presence of HIV-1 integrase or
LEDGF/p75 by immunoblotting with anti-Myc or anti-FLAG Mabs, respectively. Data shown in
figure 14b, clearly demonstrated that deletion of CR3 did not alter the capacity of LEDGF/p75 to
interact with HIV-1 integrase. These observations correlated with the data obtained in the
integrase protection assay.
In summary, the results shown above indicated that the defective HIV-1 cofactor activity
detected in LEDGF/p75 ΔCR3 or LEDGF/p75 S271A/S273A/S275A is not due to an impaired
interaction of these mutants with HIV-1 integrase.
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Figure 14. Interaction of LEDGF/p75 mutants with HIV-1 integrase. (a) Integrase protection
assay. LEDGF/p75-deficient HEK293T cells stably expressing myc-tagged HIV-1 integrase
were either transiently transfected or not with plasmids expressing LEDGF/p75 WT or mutants.
Expression levels of LEDGF/p75 proteins and HIV-1 integrase were determined by
immunoblotting with an anti-FLAG and an anti-Myc Mab, respectively.

Detection of

endogenous C-Myc was used as a loading control in these experiments. (b) Co-
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immunoprecipitation of HIV-1 integrase with LEDGF/p75 ΔCR3. LEDGF/p75-deficient
HEK293T cells were co-transfected with different FLAG-tagged LEDGF/p75 WT or mutants
and Myc-tagged HIV-1 and subject to immunoprecipitation with an anti-FLAG Mab.
Immunoprecipitated proteins were detected by immunoblotting with anti-Myc or anti-FLAG
Mabs. Mouse antibodies light chains were used as a loading control for the immunoprecipitation.
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Integrase to chromatin tethering activity of LEDGF/p75 mutants.
We next evaluated the capacity of LEDGF/p75 mutants to tether HIV-1 integrase to
chromatin (integrase to chromatin tethering assay). In this assay, we used LEDGF/p75-deficient
cells expressing HIV-1 integrase-eGFP (2LKD-IN-eGFP cells). HIV-1 integrase-eGFP was
distributed pan-cellularly in 2LKD-IN-eGFP cells during interphase (Fig. 15) and it was not
associated with condensed chromatin during mitosis (Data not shown). However, upon reexpression of LEDGF/p75 WT, this fluorescent fusion protein was dramatically localized to the
cell nuclei in interphase or to condensed chromatin during cell division (Fig. 15). However, and
as expected, this striking sub-cellular redistribution was not observed after expression of
LEDGF/p75 ΔIBD in 2LKD-IN-eGFP cells (Fig. 15).
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Figure 15. Integrase to chromatin tethering assay. LEDGF/p75-deficient HEK293T cells stably
expressing eGFP-tagged HIV-1 integrase were either transiently transfected or not with plasmids
expressing LEDGF/p75 WT or mutants and analyzed by fluorescence microscopy. Chromatin
was stained with DAPI.
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Using the integrase to chromatin tethering assay we observed that transient expression of
the four LEDGF/p75 CR mutants or LEDGF/p75 S271A/S273A/S275A consistently tethered
integrase-eGFP to the nuclear compartment and to mitotic chromosomes (Fig. 15). This effect on
integrase-eGFP localization was identical to the observed with the LEDGF/p75 WT, indicating
that mutations of these regions did not alter the tethering capacity of LEDGF/p75. These results
were also in agreement with data obtained in the chromatin-binding and integrase protection
assays.
Although a reduction in the strength of the LEDGF/p75 chromatin binding was observed
after deletion of CR2 and CR4 (Fig. 13b) this defect did not impair the capacity of these mutants
to tether integrase to chromatin in cells. Even more important, the defect of LEDGF/p75 ΔCR3
or LEDGF/p75 S271A/S273A/S275A in rescuing HIV-1 infection in TL3 cells cannot be
attributed to an impairment of the tethering capacity of these mutants.
In sum, these results clearly demonstrated that the reduced HIV-1 cofactor activity
observed in LEDGF/p75 ΔCR3 and in the LEDGF/p75 S271A/S273A/S275A is not due to
impairment of their chromatin-binding activity, HIV-1 integrase binding activity, or integrase to
chromatin tethering capability. These data strongly emphasized the relevance of LEDGF/p75
serine residues 271, 273 and 275 in the HIV-1 cofactor activity of a tethering competent
LEDGF/p75 molecule.
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2.4.

Discussion

LEDGF/p75 is a cellular cofactor of HIV-1 DNA integration [4]. However, the molecular
mechanism of this activity awaits further clarification. Analysis of LEDGF/p75 mutants
indicated that chromatin- and integrase-binding properties of this cellular protein are required for
its cofactor activity [4, 37]. These observations have led to propose a tethering mechanism where
chromatin-bound LEDGF/p75 interacts with HIV-1 integrase tethering the PIC to the host
chromatin [4]. The role of LEDGF/p75 in the HIV-1 integration site distribution further
supported this tethering model [35, 37, 41]. In addition to tethering integrase to the chromatin,
LEDGF/p75 protects the viral enzyme from proteasome-mediated degradation and increases its
enzymatic activity in vitro [40, 54]. However, it is unknown if these LEDGF/p75 functions are
also required for its HIV-1 cofactor activity.
Here we report molecular evidences of a new requirement for the HIV-1 cofactor activity
of LEDGF/p75. We have found that serine residues 271, 273 and 275 of LEDGF/p75
importantly influence its HIV-1 cofactor activity. Mutation of these amino acids to alanine
impairs the HIV-1 cofactor activity of LEDGF/p75 without altering its chromatin- or integrasebinding activities or its integrase to chromatin tethering capacity as measured by different
cellular and biochemical approaches. The level of impairment in the cofactor activity of
LEDGF/p75 caused by these point mutations is similar to levels observed in LEDGF/p75
mutants that are defective for chromatin binding. In addition, a pre-integration defect in the HIV1 viral life cycle was observed in TL3 cells expressing this mutant. These results suggest that
serine 271, 273 and 275 mediate an unknown LEDGF/p75 function that is involved in HIV-1
DNA integration.

62

Beyond the identification of a role of serine residues 271, 273 and 275 in the HIV-1
cofactor activity of LEDGF/p75, our data formally demonstrate that the CR regions of the
protein are not required for chromatin or integrase interaction. Noticeably, chromatin-binding,
integrase-binding and integrase to chromatin tethering functions of LEDGF/p75 tolerate
significant structural changes since none of the CR deletions importantly impaired them. In
contrast, the HIV-1 cofactor activity of LEDGF/p75 was more sensitive to these structural
changes. Although mutations affecting serines 271, 273 and 275 (ΔCR3, ΔCR3.1 and
S271A/S273A/S275A) markedly reduced the cofactor activity of LEDGF/p75, CR1 deletion also
decreased its activity. These results indicated that tethering HIV-1 integrase to chromatin, while
central in the molecular mechanism of LEDGF/p75 in HIV-1 infection, is not sufficient for the
full HIV-1 cofactor activity of this cellular protein.
The molecular mechanism of the serine residues 271, 273 and 275 in the HIV-1 cofactor
activity of LEDGF/p75 is not known yet. This motif is evolutionarily conserved from avian to
humans and is located in a region of LEDGF/p75 predicted to be highly exposed to the solvent
[60]. Serine residues are targeted by different post-translational modifications including:
phosphorylation, O-acetylation and O-glycosylation. Although these serines are not predicted to
be O-acetylated or O-glycosylated, they have been found phosphorylated in different global
phosphoproteomic analysis of human and mouse cells [64-71, 73]. Serine 271, 273 and 275 are
predicted to be a substrate for phosphorylation by PKCK2. This kinase phosphorylates Ser or
Thr residues in the motif S/T-X-X-E/D, where X are non-basic amino acids [72]. PKCK2dependent phosphorylation facilitates protein-protein interactions in different cellular processes
[72, 74-77]. Based on all these reported evidences we speculate that serine phosphorylation at
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this motif could influence the cofactor activity of LEDGF/p75 by facilitating its interaction with
other cellular proteins implicated in HIV-1 integration.
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Chapter 3: LEDGF/p75 is a Member of the Transcriptional Elongation Complex

3.1 Introduction
Since the inception of LEDGF/p75 characterization, a number of protein binding
partners have been described with these including cellular proteins such as JPO2, pogZ,
menin/MLL and Cdc7-ASK [78-81]. The interesting fact about all of these proteins is that they
all interact with the IBD of LEDGF/p75. In an attempt to further characterize LEDGF/p75
interactors we conducted a mass spectrometry analysis of LEDGF/p75. From this analysis a
number of potential LEDGF/p75 protein-protein interactors was revealed (Table 1). As part of
this study it was to decided move forward with SSRP1 (Structure Specific Recognition Protein 1)
and SPT16 (Suppressor of Ty 16 homolog) since they form a heterodimeric protein complex
known as FACT (FAcilitates Chromatin Transcription) which affects eukaryotic RNA
polymerase II (Pol II) transcription elongation both in vitro and in vivo [82].
The FACT complex represents a class of chromatin structure modulator known to
reorganize nucleosomal structure by the removal and/or reassembly of the histone H2A-H2B
dimers. Co-immunoprecipitation experiments done with tagged recombinant proteins have
shown that the Spt16 subunit interacts with H2A/H2B dimers and mononucleosomes, but not
H3/H4 tetramers, whereas the SSRP1 subunit interacts only with H3/H4 tetramers and not
mononucleosomes [83].
We demonstrated by co-immunoprecipitation the interaction of LEDGF/p75 with SSRP1
and Spt16, and these finding were corroborated by quantitative confocal co-localization analysis
thereby demonstrating that LEDGF/p75 is a member of the transcriptional elongation complex
(Fig 16 and 17).
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Protein

Gene

Gene ID

Species

Weight

Hits

CSE1L

XPO2

1434

Human

110 kDa

7

Dynamin-2

P50570

47117856

Human

98 kDa

9

NOP14

NOP14

8602

Human

98 kDa

33

NAT10

NAT10

55226

Human

116 kDa

21

PWP2

PWP2

5822

Human

103 kDa

27

NCBP1

NCBP1

4686

Human

92 kDa

37

P5CS

P54886

6226882

Human

87 kDa

42

FUBP2

FUBP2

8570

Human

73 kDa

23

NOL11

NOL11

25926

Human

81 kDa

26

XRCC5

KU86

7520

Human

83 kDa

42

DDX50

DDX50

79009

Human

82.5 kDa

32

SSRP1

SSRP1

6749

Human

81 kDa

9

NOL6

NOL6

65083

Human

128 kDa

3
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Table 1. Potential LEDGF/p75 Interactors. Proteins that potentially interact with LEDGF/p75
were elucidated through mass spectrometry analysis. LEDGF/p75 deficient HEK 293T were
cotransfected or not (negative control) with FLAG-tagged LEDGF/p75. Cellular extracts
containing the chromatin bound proteins were obtained and immunoprecipitated with anti-FLAG
Mab. Proteins were separated on an SDS-PAGE gel and silver stained. Bands appearing in the
sample obtained from cells expressing FLAG-tagged LEDGF/p75 but not in the non-transfected
cells were excised along with the corresponding area in the negative control. These bands were
then subjected to mass spectrometry analysis and protein hits appearing in the experimental
control and not within the negative control were designated as potential LEDGF/p75 interactors.
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3.2 Materials and Methods

Cell lines. Cell lines were derived from the human CD4+ T cell line SupT1 by stably expression
of an shRNA sequence targeting LEDGF/p75 (TL3 cells) or a control scrambled shRNA (TC3
cells). TL3 cells express 97% less LEDGF/p75 mRNA than TC3 cells as determined by real time
PCR. LEDGF/p75-deficient TL3 cells were later engineered to re-express a C-terminally FLAGtagged LEDGF/p75. HeLa cells were used for confocal colocalization studies.

Mass Spectrometry. Proteins that potentially interact with LEDGF/p75 were elucidated through
mass spectrometry analysis. LEDGF/p75 deficient HEK 293T were cotransfected or not
(negative control) with FLAG-tagged LEDGF/p75. Cellular extracts containing the chromatin
bound proteins were obtained and immunoprecipitated with anti-FLAG Mab. Proteins were
separated on an SDS-PAGE gel and silver stained. Bands appearing in the sample obtained from
cells expressing FLAG-tagged LEDGF/p75 but not in the non-transfected cells were excised
along with the corresponding area in the negative control. These bands were then subjected to
mass spectrometry analysis and protein hits appearing in the experimental control and not within
the negative control were designated as potential LEDGF/p75 interactors.

Immunoprecipitation. The interaction of the LEDGF/p75 with the FACT complex was
evaluated by immunoprecipitation using the LEDGF/p75-deficient TL3 cells engineered to
express FLAG-tagged LEDGF/p75 wild type (TL3 LEDGF/p75 WT cells). Briefly, 18x106 TL3
LEDGF/p75 WT cells were washed in PBS and lysed for 15 mins on ice in 100µl of CSK I
buffer (10mM Pipes pH6.8, 100mM NaCl, 1mM EDTA, 300mM sucrose, 1mM MgCl2, 1mM
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DTT, 0.5% Triton X-100) containing protease inhibitors (final concentration: leupeptine 2µg/ml,
aprotinin 5µg/µl, PMSF 1mM, pepstatin A 1µg/ml). Cells lysed in CSK I buffer were
centrifuged at 1000g for 6 mins at 4°C and the pellet was resuspended in 100µl of CSK II buffer
supplemented with protease inhibitors, 4 units of turbo DNase (Ambion) and 11µl of 10X turbo
DNase reaction buffer. DNase treatment of this pellet was conducted at 37°C for 30 mins and
then centrifuged at 22,000g for 3 mins and the supernatant used for immunoprecipitation using
goat anti-mouse Igs-coated magnetic beads (Pierce). Beads (100µl) were previously loaded for
20 mins on ice with 3µg of anti-FLAG Mab diluted in CSKI buffer. Then, beads were separated
from the unbound antibodies, mixed with the DNase-extracted cell lysate and rotated for 2hrs at
4°C. After this incubation, beads were washed three times in CSKI buffer and bound proteins
eluted by boiling in 30µl of Laemmli sample buffer. Immunoprecipitated proteins were analyzed
by immunoblotting for the presence of the components of the FACT complex: SSRP1 (Santa
Cruz, sc-56782) and Spt16 (Santa Cruz, sc-28734). LEDGF/p75 was detected with anti-FLAG
Mab (Sigma, F1804).

Quantitative co-localization assay. Co-localization was evaluated with a confocal microscope
using the Zeiss Zen software. In order to set up this method we evaluated co-localization of
LEDGF/p75 with HIV-1 integrase. These proteins interact during all the phases of the cell cycle.
As a negative control a LEDGF/p75 mutant lacking the integrase binding domain (IBD) was
used. LEDGF/p75-deficient HEK 293T cells stably expressing eGFP-tagged HIV-1 integrase
(2LKD-IN-eGFP cells) were plated at 2x105 cells in LabTek II chambered coverglasses and
transfected the next day with 2ug of pFLAG-LEDGF/p75 WT or IBD deletion mutant. Eighteen
hrs after transfection fresh culture medium was added and forty-eight hours later cells were
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washed three times in PBS and fixed with 4% formaldehyde-PBS for 10 min at 37°C. Then, cells
were washed twice in PBS and immunostained for 2 hrs at 37ºC. LEDGF/p75 was detected with
an anti-mouse LEDGF Mab diluted 1/100 (clone 26, BD Transduction Laboratories) or an antirabbit LEDGF polyclonal antibody (Pab) diluted 1/100 (Bethyl Laboratories, A300-848A)
followed by incubation with anti-mouse Ig coupled to Alexa Fluor 594 (10 µg / ml, Invitrogen
A21203) or with an anti-rabbit Ig coupled to Alexa Flour 488 (10 µg/ml, Invitrogen A21206).
Immunostained cells were washed and stained with DAPI. Colocalization of LEDGF/p75 with
HIV-1 eGFP-integrase was analyzed with a confocal microscope and the Zeiss Zen software. In
order to measure co-localization of LEDGF/p75 with proteins of the transcriptional apparatus
2x105 HeLa cells were plated in LabTek II chambered coverglasses and immunostained as
described above. Antibodies against SSRP1 (Santa Cruz, sc-56782) and Spt16 (Santa Cruz, sc28734) were used. Secondary antibodies, DAPI staining and colocalization analysis was
performed as described above.
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3.3 Results
Interaction of LEDGF/p75 with proteins involved in transcription. LEDGF/p75-deficient
SupT1 cells (TL3 cells) and TL3 cells expressing FLAG-tagged LEDGF/p75 were subjected to
immunoprecipitation with an anti-FLAG Mab. Immunoprecipitated proteins were then evaluated
by immunoblotting for the presence of different components of the elongation complex, the
heterodimer SSRP1/Spt16 or FACT complex. The FACT complex remodels nucleosomes in an
ATP-independent fashion allowing Pol II to access the DNA during transcriptional elongation
[82].
SSRP1 exists in a chromatin-bound and a non-chromatin bound fractions. Therefore, in
order to evaluate the interaction of LEDGF/p75 with the FACT complex forms involved in
transcriptional elongation, we lysed the cells in a buffer containing 0.1% Triton X-100 and 100
mM NaCl (CSK1 buffer). This buffer has been reported to extract only chromatin non-bound
proteins. Chromatin-bound proteins were then released from the insoluble fraction of the CSKIcellular lysate by extensive treatment with DNase. The DNase-released chromatin-bound
proteins were then subjected to FLAG immunoprecipitation and coimmunoprecipitated proteins
were evaluated for the presence of the FACT complex by immunoblotting with specific
antibodies. Results included in figure 16 indicate that LEDGF/p75 is associated in vivo with both
subunits, SSRP1 and Spt16, of the FACT complex, which are involved in transcriptional
elongation. Since chromatin-bound proteins were extracted by DNAse treatment before
immunoprecipitation, the association of LEDGF/p75 with these members of the transcriptional
elongation complex is independent of DNA.
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Figure 16. Interaction of LEDGF/p75 with components of the elongation complex. Chromatinbound proteins were isolated from TL3 and TL3 LEDGF/p75 WT cells by DNAse and salt
treatment and FLAG-tagged LEDGF/p75 was immunoprecipitated with an anti-FLAG Mab. The
presence of the FACT complex (Spt16 and SSRP1) was evaluated in the immunoprecipitated
proteins by immunoblotting with specific antibodies.
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To further verify the interaction of LEDGF/p75 with SSRP1 we preformed a quantitative
confocal colocalization analysis (Fig. 17). As control, we calculated the co-localization of HIV-1
integrase (IN) with LEDGF/p75 WT or a mutant lacking the integrase binding domain (ΔIBD).
In correlation with previously reported data, LEDGF/p75 WT fully co-localized with IN and this
co-localization was lost upon deletion of IBD (Fig. 17a-I). LEDGF/p75 WT significantly colocalized

with

SSRP1.

Co-localization

with

SSRP1

validated

the

results

of

the

immunoprecipitation experiment included in figure 16. Results presented in figures 16 and 17
clearly indicate that LEDGF/p75 interacts with components of the transcriptional elongation
complex.

74

Figure 17. Quantitative confocal colocalization of LEDGF/p75 with proteins of the
transcriptional machinery. Colocalization controls. Colocalization of LEDGF/p75 and HIV
integrase were used as controls. LEDGF/p75-deficient HEK293T cells stably expressing Myctagged HIV-1 integrase were transiently transfected with LEDGF/p75 WT or a mutant lacking
the integrase-binding domain (IBD). LEDGF/p75 and integrase were detected with anti-LEDGF
and anti-Myc antibodies, respectively. Colocalization of LEDGF/p75 with SSRP1. HeLa cells
were fixed and immunostained with specific antibodies. Histograms and representative cells are
shown.
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3.4 Discussion
A role of LEDGF/p75 in transcriptional regulation at promoters regions has been
extensively described, yet the participation of LEDGF/p75 in other steps of transcriptional
regulation has not been evaluated. Co-transfection of LEDGF/p75 with several promoters of
stress responsive genes indicated that LEDGF/p75 regulates the transcription of these genes by
binding to specific DNA sequences in their promoters [35]. However, the specific interaction of
LEDGF/p75 with these sequences was not supported in an independent study. At the molecular
level, it was demonstrated in in vitro studies that LEDGF/p75 activated transcription of reporter
promoters by linking promoter-specific transcription factors with components of the basal
transcription machinery. In addition, it was demonstrated LEDGF/p75 regulates the
transcriptional activity of the Hox A9 gene by tethering to the promoter of this gene the histone
methyl transferase menin/MLL complex [79]. Interestingly, a similar molecular tethering
mechanism is involved in the role of LEDGF/p75 in HIV DNA integration.
LEDGF/p75 tethers the HIV-1 pre-integration complex to the host chromatin facilitating
viral DNA integration into the host DNA. This interaction targets HIV-1 to integrate inside genes
that are actively transcribed. In correlation with this, genome-wide location of LEDGF/p75
indicated that this protein is enriched inside actively transcribed genes [35]. In correlation with
these experimental evidences, we found that LEDGF/p75 colocalized in vivo with the FACT
complex, a component of the transcriptional elongation complex. Interaction with the
transcriptional elongation active forms of the FACT complex was also further evidenced to occur
in vivo and to be independent of DNA.
We do not understand yet the role of LEDGF/p75 in the transcriptional elongation
complex. However, it could be involved in tethering the histone methyltransferase menin/MLL
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complex to the transcription unit to catalyze trimethylation of lysine 4 on histone H3, an
epigenetic mark associated with transcriptionally active chromatin and activity of P-TEFb. A
similar role has been reported for the yeast COMPASS (Complex Proteins Associated with Set1)
complex which is a functional analog of the human MLL [84]. The COMPASS complex is
recruited by Pol II (phosphorylated at serine 5 in the C-terminal domain) to trimethylate lysine 4
on histone H3, a modification highly correlated with transcriptional elongation [85]. It is also
possible that LEDGF/p75 participates in attracting to these subset of genes other components of
the elongation complex.
In addition, we postulate that the presence of LEDGF/p75 at the elongation complex will
facilitate HIV DNA integration by allowing the virus to exploit the cellular function of other
members of this complex. For instance, the FACT complex could assist the HIV preintegration
complex to gain access to the host DNA in a similar manner that FACT facilitates DNA access
to the RNA polymerase during transcription. Similarly, the interaction of LEDGF/p75 with the
component of the FACT complex, SSRP1, could facilitate post-integration DNA repair. SSRP1
has a role in transcription-coupled DNA repair. This is a subpathway of the nucleotide excision
repair pathway that is responsible for removing DNA lesions in actively transcribed DNA
strands that cause RNA polymerase to stall during transcription. HIV has a bias for integration
inside actively transcribed genes [35]. Therefore, it is likely that HIV integration will cause arrest
of transcription of the integration target genes. The interaction of LEDGF/p75 with SSRP1
would give an advantage to the virus to initiate efficient DNA repair following viral DNA
integration. Since LEDGF/p75 is a member of the elongation complex it will be also
advantageous for the virus the interaction with LEDGF/p75 to dock into chromatin areas that are
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engaged in active transcription allowing efficient viral gene expression rapid after viral
integration.
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Chapter 4: Final Conclusions and Future Directions

5.1.

Overview and Final Conclusions
Throughout the past years many significant strides have been made in regards to the role

LEDGF/p75 plays in HIV-1 infection. Since the discovery that LEDGF/p75 coimmunoprecipitates with HIV-1 integrase much work has been done in an effort to further
understand the molecular mechanism by which it interplays with other factors within the cell in
order for integration to occur.
At the inception of this dissertation work, three main functional domains within
LEDGF/p75 had been described, with this being: the Chromatin Binding Domain (CBD), which
constitutes the functional interaction of the PWWP domain and two AT hook motifs, the Nuclear
Localization Signal (NLS), and the Integrase Binding Domain (IBD). As part of my contribution
to the HIV-1 field my work focused on further characterizing other potential functional regions
within the LEDGF/p75 protein which met the following criteria: (1) The regions had to be
evolutionarily conserved from amphibians to humans. (2) They had to contain clusters of
charged residues. (3) These regions could serve as potential targets of post-translational
modifications.
From the results obtained in this study it was concluded that three serine residues
(S271/S273/S275) within LEDGF/p75 have a role in HIV-1 infectivity. Although the exact
mechanism by which this occurs has not yet been elucidated, we hypothesize that CK2 is
interacting with this region since the motif present within the region is a predicted CK2
phosphorylation site. One could speculate that this serine motif could serve as a docking site for
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other cellular proteins that participate in HIV-1 DNA integration and that the prevention of this
putative interaction could be an attractive target for drug development (Fig. 18)
Another region that was found to be involved in LEDGF/p75’s HIV-1 cofactor activity
was CR1. The deletion of this region resulted in a reduction of LEDGF/p75’s cofactor activity to
41% when compared to WT. Now although these regions are implicated in HIV-1 infection they
do not alter the ability of LEDGF/p75 to tether HIV-1 integrase to chromatin indicating the
existence of chromatin tethering independent mechanisms in the molecular mechanism of
LEDGF/p75 in HIV-1 infection.
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Figure 18. Research Implications. The S271/S273/S275 motif could serve as a potential drug
target site with which a competitive binder could be developed in order to block the interaction
of cellular factors with this region and potentially suppress HIV-1 integration.
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The discovery of the implication of the serine motif and the potential involvement of
other cellular factors with LEDGF/p75 lead us to conduct a proteomic analysis of LEDGF/p75
and characterize protein-protein interactors through the use of mass spectrometry. Our
hypothesis is that LEDGF/p75 may be forming a complex with other cellular factors important
for HIV-1 infection as well as the cellular functions of LEDGF/p75. Through this work we
elucidated a number of potential LEDGF/p75 interactors and verified by co-immunoprecipitation
the interaction of LEDGF/p75 with SSRP1 and SPT16. These two proteins form a heterodimer
known as the FACT (FAcilitates Chromatin Transcription) complex, which is involved in
transcriptional elongation. Furthermore, we demonstrated the interaction of LEDGF/p75 with
this complex by quantitative confocal co-localization studies, which evaluated the direct
interaction of LEDGF/p75 with this complex. These findings correlate with other data obtained
within the laboratory implicating LEDGF/p75 in the transcriptional elongation complex.
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5.2.

Future Directions
The further characterization of the interaction of LEDGF/p75 and FACT is vital to

understanding the role LEDGF/p75 plays in regard to HIV-1 integration and cellular
transcriptional elongation. Work such as the mapping of which region(s) within LEDGF/p75 are
implicated in this interaction would provide insight into the nature of this interaction. In addition
the direct role of the FACT complex in HIV-1 DNA integration can be explored in cells
transiently depleted of SSRP1 and Spt16 since stable knockdown are not viable.
In summary, our data indicates for the first time the implication of chromatin tetheringindependent mechanisms in the molecular mechanism of LEDGF/p75 in HIV-1 infection.
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Appendix
List of Abbreviations
ATR

Ataxia talangiectasia-mutated kinase

AIDS

Acquired immune deficiency syndrome

CBD

Chromatin binding domain

COMPASS

Complex Proteins Associated with Set 1

CR

Charged region

DAPI

4′,6-diamidino-2-phenylindole

DC

Dendritic cells

DC-SIGN

Dendritic cell-specific ICAM-3 grabbing non-integrin

DMEM

Dulbecco's modified Eagle's medium

DSB

Double-stranded breakage

FACT

Facilitates Chromatin Transcription

gp120

glycoprotein 120

HIV-1

Human immunodeficiency virus-1

IBD

Integrase binding domain

IN

HIV-1 integrase

LEDGF

Lens-epithelium-derived growth factor

LTR

Long terminal repeat

mAb

Monoclonal antibody

NBS1

Nijmegen breakage syndrome-1 protein

NHEJ

Non homologous end joining

PBS

Phosphate-buffered saline
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PIC

Preintegration complex

PIR

Post-integration repair

PWWP

Pro-Trp-Trp-Pro motif

shRNA

Short hairpin RNA

Spt16

Suppressor of Ty 16 homolog

SSRP1

Structure Specific Recognition Protein 1

TBS

Tris-buffered saline

WT

Wild type
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Figure S1. LEDGF/p75 protein sequences alignment. Sequences from the NCBI protein
database were aligned using ClustalW2. Hs, Homo sapiens (NM 033222.3); Cf, Canis familiaris
(XP_531939); Fc, Felis catus (AAU10509); Bt, Bos taurus (AAM90841.1); Ec, Equus caballus
(ABH11544.1); Mc, Macaca mulatta (ABD77428); Mm, Mus musculus (Q99JF8); Rn, Rattus
norvegicus (NP_786941); Md, Monodelphis domestica (XP_001366101); Gg, Gallus gallus
(NP_001026781.2); Xl, Xenopus laevis (NP_001089191); Oa, Ornithorhynchus anatinus
(XP_001507936.1); Tn, Tetraodon nigroviridis (CAG07956) and Ss, Salmo salar (ACI34089).
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Mutant
ΔPWWP

Deletion
1-93

Primers
TTCTCGAGGGATCCCCGGGTACCGAGCTC
ATCGATGAGTCAACAGGCAGCAACTAAAC

ΔATH

178-198

ACTCACTTTTAGATTAACAGATGC
ATGGTAAAACAGCCCTGTCCTTCAG

ΔPWWP/ ΔATH

See above

See primers used for single deletion mutants

ΔIBD

340-442

TTTCTTAACTTCTGGCTTCTTTCC
TCTCTTGCTGAACAACGGCAACACG

ΔCR1

94-145

TGAAAATTTCACTTTTGGATTGTTATC
AGAAGGGGGAGAAAGAGAAAGGCAG

ΔCR2

199-266

TTTGGGTCTGCCTCTTGGTTTTGG
ACAGGGGTTACTTCAACCTCCGATTC

ΔCR3

267-325

TTTAGCTAAATTTTTCCTTTTTGATTC
CAGCAGAATAAAGATGAAGGAAAGAAG

ΔCR4

326-339

CTCAGTTTCCATTTGTTCCTCTTGCTTG
GTGGAGAAGAAGCGAGAAACATCAATG
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ΔCR5

443-530

TGTAGACTTTTCCATGATTACCTGAC
GGGCCCGACTACAAAGACGATGACG

ΔCR3.1

267-281

TTTAGCTAAATTTTTCCTTTTTGATTC
CAAGAA GGTGAAAAGAAGAGAAAAGG

ΔCR3.2

282-325

ATCATCTCCTTCTTCTTCAGAATCGG
CAGCAGAATAAAGATGAAGGAAAGAAG

ΔCR3.3

303-325

CATATTCCTTCTGTGAGCAGTCTGAAAG
CAGCAGAATAAAGATGAAGGAAAGAAG

S271A/S273A/S275A None

TTTAGCTAAATTTTTCCTTTTTGATTC
ACAGGGGTTACTGCAACCGCCGATGCTGAAG

S271A

None

TTTAGCTAAATTTTTCCTTTTTGATTC
ACAGGGGTTACTGCAACCTCCGATTCTGAAG

S273A

None

TTTAGCTAAATTTTTCCTTTTTGATTC
ACAGGGGTTACTTCAACCGCCGATTCTGAAG

S275A

None

TTTAGCTAAATTTTTCCTTTTTGATTC
ACAGGGGTTACTTCAACCTCCGATGCTGAAG
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Table 2. LEDGF/p75 mutants. Mutants were generated by PCR with the listed primers. The
amino acids deleted are indicated. Primer sequences are written from the 5’ end to the 3’ end.
For each mutant, the reverse primer is listed first followed by the forward primer.
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